Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics

References

• Statista: The Statistics Portal. Global top 10 companies based on biotech prescription drug revenue in 2017 and 2024. 2018 June [ accessed 2018 Oct 5]. https://www.statista.com/statistics/309460/biotechnology-prescription-drug-revenue-by-top-ten-companies-globally/.
   Google Scholar
• Stone K. Top 10 biologic drugs in the United States: these drugs are changing the way illnesses are treated. 2018 [ accessed 2018 Oct 5]. https://www.thebalance.com/top-biologic-drugs-2663233.
   Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs. 2018;10:183–203. doi:10.1080/19420862.2018.1415671.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Guidance for Industry. Silver Spring (MD): United States Food and Drug Administration; 2015.
   Google Scholar
• Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11:527–540. doi:10.1038/nrd3746.
   PubMed Web of Science ®Google Scholar
• Borisov OV, Schiel JE, Davis D. Trends and drivers for the development of next-generation biotherapeutic characterization tools. In: Schiel JE, Davis DL, Borisov OV, editors. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization, vol 3: defining the next generation of analytical and biophysical techniques. Washington (DC): American Chemical Society; 2015. p. 1–16.
   Google Scholar
• Weiss WF, Gabrielson JP, Al-Azzam W, Chen G, Davis DL, Das TK, Hayes DB, Houde D, Singh SK. Technical decision making with higher order structure data: perspectives on higher order structure characterization from the biopharmaceutical industry. J Pharm Sci. 2016;105:3465–3470. doi:10.1016/j.xphs.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Fisher AC, Lee SL, Harris DP, Buhse L, Kozlowski S, Yu L, Kopcha M, Woodcock J. Advancing pharmaceutical quality: an overview of science and research in the U.S. FDA’s Office of Pharmaceutical Quality. Int J Pharm. 2016;515:390–402. doi:10.1016/j.ijpharm.2016.10.038.
   PubMed Web of Science ®Google Scholar
• Gabrielson JP, Weiss WF. Technical decision-making with higher order structure data: starting a new dialogue. J Pharm Sci. 2015;104:1240–1245. doi:10.1002/jps.24393.
   PubMed Web of Science ®Google Scholar
• Aubin Y, Gingras G, Sauve S. Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on recombinant human granulocyte macrophage-colony stimulation factor. Anal Chem. 2008;80:2623–2627. doi:10.1021/ac7026222.
   PubMed Web of Science ®Google Scholar
• Japelj B, Ilc G, Marusic J, Sencar J, Kuzman D, Plavec J. Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies. Sci Rep. 2016;6:32201. doi:10.1038/srep32201.
   PubMed Web of Science ®Google Scholar
• Kiss R, Fizil Á, Szántay C. What NMR can do in the biopharmaceutical industry. J Pharm Biomed Anal. 2018;147:367–377. doi:10.1016/j.jpba.2017.07.004.
   PubMed Web of Science ®Google Scholar
• Aubin Y, Freedberg DI, Jones C. Using NMR spectroscopy to obtain the higher order structure of biopharmaceutical products: simple methods can characterize polysaccharide vaccines and recombinant cytokines at high resolution. Biopharm Int. 2010;S28+.
   Google Scholar
• Arbogast LW, Brinson RG, Marino JP. Application of natural isotopic abundance (1)H-(13)C- and (1)H-(15)N-correlated two-dimensional NMR for evaluation of the structure of protein therapeutics. Methods Enzymol. 2016;566:3–34. doi:10.1016/bs.mie.2015.09.037.
   PubMed Web of Science ®Google Scholar
• Ghasriani H, Hodgson DJ, Brinson RG, McEwen I, Buhse LF, Kozlowski S, Marino JP, Aubin Y, Keire DA. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars. Nat Biotechnol. 2016;34:139–141. doi:10.1038/nbt.3474.
   PubMed Web of Science ®Google Scholar
• Aubin Y, Hodgson DJ, Thach WB, Gingras G, Sauve S. Monitoring effects of excipients, formulation parameters and mutations on the high order structure of filgrastim by NMR. Pharma Res. 2015;32:3365–3375. doi:10.1007/s11095-015-1713-3.
   Google Scholar
• Singh SM, Bandi S, Jones DNM, Mallela KMG. Effect of polysorbate 20 and polysorbate 80 on the higher-order structure of a monoclonal antibody and its fab and fc fragments probed using 2d nuclear magnetic resonance spectroscopy. J Pharm Sci. 2017;106:3486–3498. doi:10.1016/j.xphs.2017.08.011.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Clinical Pharmacology Data to Support Demonstration of Biosimilarity to a Reference Product: Guidance for Industry. United States Food and Drug Administration, Silver Spring (MD): 2016.
   Google Scholar
• Arbogast LW, Brinson RG, Marino JP. Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance. Anal Chem. 2015;87:3556–3561. doi:10.1021/ac504804m.
   PubMed Web of Science ®Google Scholar
• Arbogast LW, Brinson RG, Formolo T, Hoopes JT, Marino JP. 2D (1)H(N), (15)N correlated NMR methods at natural abundance for obtaining structural maps and statistical comparability of monoclonal antibodies. Pharm Res. 2016;33:462–475. doi:10.1007/s11095-015-1802-3.
   PubMed Web of Science ®Google Scholar
• Hodgson DJ, Ghasriani H, Aubin Y. Assessment of the higher order structure of Humira(R), Remicade(R), Avastin(R), Rituxan(R), Herceptin(R), and Enbrel(R) by 2D-NMR fingerprinting. J Pharm Biomed Anal. 2019;163:144–152. doi:10.1016/j.jpba.2018.09.056.
   PubMed Web of Science ®Google Scholar
• Schiel JE, Mire-Sluis, A, David D. Monoclonal Antibody Therapeutics: The Need for Biopharmaceutical Reference Materials. In: Schiel JE, Davis DL, Borisov OV, editors. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space. Washington (DC): American Chemical Society; 2014. p. 1-34.
   Google Scholar
• Schiel JE, Turner A. The NISTmAb Reference Material 8671 lifecycle management and quality plan. Anal Bioanal Chem. 2018;410:2067–2078. doi:10.1007/s00216-017-0844-2.
   PubMed Web of Science ®Google Scholar
• Schiel JE, Turner A, Mouchahoir T, Yandrofski K, Telikepalli S, King J, DeRose P, Ripple D, Phinney K. The NISTmAb Reference Material 8671 value assignment, homogeneity, and stability. Anal Bioanal Chem. 2018;410:2127–2139. doi:10.1007/s00216-017-0800-1.
   PubMed Web of Science ®Google Scholar
• Arbogast LW, Delaglio F, Schiel JE, Marino JP. Multivariate analysis of two-dimensional 1H, 13C methyl NMR spectra of monoclonal antibody therapeutics to facilitate assessment of higher order structure. Anal Chem. 2017;89:11839–11845. doi:10.1021/acs.analchem.7b03571.
   PubMed Web of Science ®Google Scholar
• Schanda P, Kupce E, Brutscher B. SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR. 2005;33:199–211. doi:10.1007/s10858-005-4425-x.
   PubMed Web of Science ®Google Scholar
• Mobli M, Hoch JC. Nonuniform sampling and non-Fourier signal processing methods in multidimensional NMR. Prog Nucl Magn Reson Spectrosc. 2014;83:21–41. doi:10.1016/j.pnmrs.2014.09.002.
   PubMed Web of Science ®Google Scholar
• Williamson MP. Using chemical shift perturbation to characterise ligand binding. Prog Nucl Magn Reson Spectrosc. 2013;73:1–16. doi:10.1016/j.pnmrs.2013.02.001.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products. London, UK: 2005, CPMP/ICH/5721/03, step 5.
   Google Scholar
• United States Food and Drug Administration. Considerations in Demonstrating Interchangeability With a Reference Product: Draft Guidance for Industry. Silver Spring (MD): United States Food and Drug Administration; 2017.
   Google Scholar
• Hyberts SG, Takeuchi K, Wagner G. Poisson-gap sampling and forward maximum entropy reconstruction for enhancing the resolution and sensitivity of protein NMR data. J Am Chem Soc. 2010;132:2145–2147. doi:10.1021/ja908004w.
   PubMed Web of Science ®Google Scholar
• Schiel JE, Davis DL, Borisov, OV. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 2. biopharmaceutical characterization: the NISTmAb case study. Washington (DC): American Chemical Society; 2015;1201.
   Google Scholar
• Schiel JE, Davis DL, Borisov, OV. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 1. monoclonal antibody therapeutics: structure, function, and regulatory space. Washington (DC): American Chemical Society; 2014;1176.
   Google Scholar
• Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6:277–293.
   PubMed Web of Science ®Google Scholar
• Grzesiek S, Bax A. The importance of not saturating H2O in protein NMR. Application to sensitivity enhancement and NOE measurements. J Am Chem Soc. 1993;115:12593–12594. doi:10.1021/ja00079a052.
   Web of Science ®Google Scholar
• Sklenár V, Piotto M, Leppik R, Saudek V. Gradient-tailored water suppression for 1H - 15N HSQC experiments optimized to retain full sensitivity. J Magn Reson A. 1993;102:241–245. doi:10.1006/jmra.1993.1098.
   Google Scholar
• Worley B, Powers R. Deterministic multidimensional nonuniform gap sampling. J Magn Reson. 2015;261:19–26. doi:10.1016/j.jmr.2015.09.016.
   PubMed Web of Science ®Google Scholar
• Hyberts SG, Milbradt AG, Wagner AB, Arthanari H, Wagner G. Application of iterative soft thresholding for fast reconstruction of NMR data non-uniformly sampled with multidimensional Poisson Gap scheduling. J Biomol NMR. 2012;52:315–327. doi:10.1007/s10858-012-9611-z.
   PubMed Web of Science ®Google Scholar
• Lee W, Tonelli M, Markley JL. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics. 2015;31:1325–1327. doi:10.1093/bioinformatics/btu830.
   PubMed Web of Science ®Google Scholar
• Markley JL, Bax A, Arata Y, Hilbers CW, Kaptein R, Sykes BD, Wright PE, Wüthrich K. Recommendations for the presentation of NMR structures of proteins and nucleic acids. IUPAC-IUBMB-IUPAB inter-union task group on the standardization of data bases of protein and nucleic acid structures determined by NMR spectroscopy. J Biomol NMR. 1998;12:1–23.
   PubMed Web of Science ®Google Scholar
• Wenrich BR, Sonstrom RE, Gupta RA, Rovnyak D. Enhanced biosynthetically directed fractional carbon-13 enrichment of proteins for backbone NMR assignments. Protein Expr Purif. 2015;115:1–10. doi:10.1016/j.pep.2015.08.005.
   PubMed Web of Science ®Google Scholar
• Kaufman L, Rousseeuw PJ. Clustering by means of medoidss. In: Diodge Y, editor. Statistical data analysis based on the L_1 Norm and Related Methods. North Holland (MI): University of Michigan; 1987. p. 464.
   Google Scholar
• Sokal RR. A statistical method for evaluating systematic relationship. Univ Kans Sci Bull. 1958;28:1409–1438.
   Google Scholar
• Kaufman L, Rousseeuw PJ. Finding groups in data: an introduction to cluster analysis. Hoboken (NJ): John Wiley & Sons, Inc; 2005.
   Google Scholar